Results 141 to 150 of about 4,832 (178)

Case Report: A potential novel treatment for drug-induced acute interstitial nephritis: Benralizumab. [PDF]

Front Immunol
Saadia A, Wald R, Potruch A, Pizov G, Meir K, Gorin K, Sarig I, Dori EB, Rubin L, Ribak Y, Shamriz O, Tal Y, Talmon A.   +12 more
europepmc   +1 more source

From Inflammation to Precision Medicine: Mechanistic Insights into Asthma, COPD, and IPF. [PDF]

Biomedicines
Ghrairi N, Elhechmi YZ, Ben Saad S.
europepmc   +1 more source

Benralizumab for asthma.

Australian prescriber
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Benralizumab for the treatment of asthma

Expert Review of Clinical Immunology, 2017
Benralizumab is a humanized monoclonal antibody directed at the a subunit of the interleukin-5 receptor (IL-5R) that is under clinical development. The binding of benralizumab with the alpha chain of IL-5R results in inhibition of hetero-oligomerization of alpha and beta subunits and thus no signal transduction occurs.
Tara Vinyette Saco, Amber N Pepper
exaly   +6 more sources

Benralizumab: First Global Approval

Drugs, 2018
Kyowa Hakko Kirin, AstraZeneca and subsidiaries are developing benralizumab (Fasenra™)-a humanised anti-interleukin-5 receptor alpha chain (IL-5Rα) monoclonal antibody-as a treatment of severe eosinophilic asthma and chronic obstructive pulmonary disease (COPD).
A. Markham, Anthony Markham (4891627)
openaire   +3 more sources

Benralizumab

Reactions Weekly
  +12 more sources

Benralizumab

Reactions Weekly, 2022
  +7 more sources

Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life Study [PDF]

Journal of Clinical Medicine
Background: Benralizumab has been shown to restore good control of severe eosinophilic asthma (SEA). Robust data on benralizumab effectiveness over periods longer than 2 years are scarce.
Francesco Blasi, Gianenrico Senna, Martina Zappa   +2 more
exaly   +2 more sources

Benralizumab

Reactions Weekly, 2023
openaire   +2 more sources

Benralizumab as a potential treatment of asthma

Expert Opinion on Biological Therapy, 2017
Current anti-inflammatory asthma therapies including inhaled corticosteroids and leukotriene modifiers, are not always able to appropriately control the disease and other approaches are needed. These therapies specific target IgE (omalizumab) or IL-5 (mepolizumab).
openaire   +2 more sources